Pancreatic Cancer Diagnostic Market - By Product (Instruments, Consumables), Test Type (Imaging [CT, MRI, Ultrasound, PET], Biopsy, Blood Test [Liver Function, Tumor Marker]), Cancer Type (Exocrine, Endocrine), End-use– Global Forecast (2024 – 2032)

Pancreatic Cancer Diagnostic Market - By Product (Instruments, Consumables), Test Type (Imaging [CT, MRI, Ultrasound, PET], Biopsy, Blood Test [Liver Function, Tumor Marker]), Cancer Type (Exocrine, Endocrine), End-use– Global Forecast (2024 – 2032)

Pancreatic Cancer Diagnostic Market Size

Pancreatic Cancer Diagnostic Market size was valued at around USD 6 billion in 2023 and is estimated to grow at 9.1% CAGR from 2024 to 2032. Pancreatic cancer diagnostics involve various methods and technologies used to detect and evaluate pancreatic cancer. This encompasses a range of procedures, tests, and tools aimed at identifying the presence of cancerous cells in the pancreas, determining the stage and extent of the disease, and guiding treatment decisions.
 

The incidence of pancreatic cancer is on the rise globally, becoming a significant health concern. This increase is attributed to factors such as aging populations, lifestyle changes, and environmental influences. Pancreatic cancer remains one of the most lethal forms of cancer due to its typically late diagnosis and rapid progression. The growing number of cases underscores the urgent need for improved diagnostic methods that can detect the disease at an earlier, more treatable stage.
 

For instance, in 2024, the American Cancer Society estimates that approximately 66,440 individuals in the U.S. will be diagnosed with pancreatic cancer, with 34,530 men and 31,910 women affected. Additionally, the disease is expected to cause around 51,750 deaths, including 27,270 men and 24,480 women. Thus, this escalating prevalence is a critical driver for the pancreatic cancer diagnostic market, pushing for the development and adoption of more effective screening and diagnostic tools.
 

Furthermore, advancements in diagnostic technologies are transforming pancreatic cancer detection. Innovations such as enhanced imaging, next-generation sequencing which is estimated to reach USD 47 billion by 2032, liquid biopsies, and advanced biomarker assays enable earlier and more accurate detection. These technologies improve diagnostic precision and facilitate personalized treatment by providing detailed molecular and genetic insights. This continuous technological evolution stimulates the market, offering hope for earlier intervention and improved patient outcomes.
 

Pancreatic Cancer Diagnostic Market Trends

• The global rise in healthcare spending stimulates the market by allocating resources to advanced diagnostic tools and technologies. This financial commitment enables healthcare providers to adopt cutting-edge solutions, improving the standard of care. Moreover, increased funding also supports ongoing research, fostering innovation in diagnostics.
   
• Therefore, healthcare spending directly enhances the accessibility of advanced diagnostic options for pancreatic cancer worldwide.
   
• Further, growing awareness about early detection's critical role in improving pancreatic cancer outcomes is prompting increased screening uptake and more rigorous diagnostic protocols.
   
• Campaigns and education emphasize that early diagnosis significantly boosts treatment success and survival rates. Thus, there's a rising demand for reliable diagnostics, propelling the market's growth. This underscores the pivotal role of education in fostering proactive health approaches and early intervention against pancreatic cancer.
   

Pancreatic Cancer Diagnostic Market Analysis

Based on product, the market is divided into instruments and consumables. The consumables segment of the market is forecasted to reach USD 6.9 billion by 2032.
 

• With pancreatic cancer rates surging globally, there's an urgent need for advanced diagnostic methods to detect the disease early. Biopsy needle, cytology brushes, and specimen collection devices are indispensable tools facilitating the retrieval of tissue samples crucial for accurate pathological examination.
   
• Simultaneously, technological innovations have unlocked novel biomarkers linked to pancreatic cancer, propelling the demand for consumables such as reagents, assay kits, and molecular probes. These consumables are instrumental in detecting biomarkers in various samples, such as blood, urine, or tissue, fueling the growth of biomarker-based diagnostic tests within the market.
   

Based on test type, the pancreatic cancer diagnostic market is bifurcated into imaging test, biopsy, blood test, and other test types. The imaging test segment accounted for USD 2.2 billion in 2023.
 

• Modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans offer detailed insights into the structure and function of the pancreas, facilitating early detection and precise localization of tumors.
   
• Additionally, the non-invasive nature of imaging tests minimizes patient discomfort and risk, making them preferable options for both clinicians and patients alike.
   
• Furthermore, the growing awareness campaigns and screening programs aimed at high-risk individuals have spurred the demand for routine imaging screenings, stimulating the growth of this segment.
   

Based on cancer type, the pancreatic cancer diagnostic market is bifurcated into exocrine and endocrine. The exocrine segment accounted for USD 5.6 billion in 2023.
 

• Exocrine pancreatic cancer, including adenocarcinoma, is the most common type of pancreatic cancer, comprising about 95% of cases. This prevalence underscores the necessity for diagnostic tests tailored to detect and monitor this specific subtype.
   
• Compounded by its tendency to present with nonspecific symptoms, diagnosing exocrine pancreatic cancer early remains challenging, contributing to its high mortality rate.
   
• Therefore, there's a critical need for reliable diagnostic tools to enable early intervention and enhance patient outcomes. This urgency amplifies the demand for diagnostic tests specifically designed for exocrine pancreatic cancer, highlighting the importance of innovative solutions in improving prognosis and survival rates.
   
• Thus, the aforementioned factor propels the segmental growth.
   

Based on end-use, the pancreatic cancer diagnostic market is bifurcated into hospitals and clinics, diagnostic laboratories, diagnostic imaging centers, and cancer research institutes. The hospitals and clinics segment accounted for USD 2.4 billion in 2023.
 

• Hospitals and clinics offer convenience, advanced diagnostic technologies, and a multidisciplinary team of healthcare professionals specialized in cancer diagnosis and treatment. Their integrated healthcare ecosystem, coupled with a robust referral network and insurance coverage, further enhances patient access to pancreatic cancer diagnostics.
   
• Therefore, the hospitals and clinics segment's prominence underscores its critical contribution to propelling the market growth through efficient and high-quality diagnostic care for pancreatic cancer.
   

• The growth of the pancreatic cancer diagnostic market in the U.S., projected to reach USD 4.7 billion by 2032.
   
• In the U.S., the advancement of diagnostic technologies, including imaging modalities such as MRI systems, CT scanner, and PET scans, alongside molecular diagnostics and biomarker identification, has revolutionized the detection and management of pancreatic cancer.
   
• These innovations have significantly enhanced the accuracy and early detection of the disease, allowing for better diagnosis and staging. By enabling healthcare professionals to visualize tumors with unprecedented clarity, identify metastases, and personalize treatment plans based on individual risk profiles, these technologies have led to improved patient outcomes and reduced the burden of pancreatic cancer in the region.
   

The pancreatic cancer diagnostic market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The incidence of pancreatic cancer has been on a consistent upward trajectory in the UK in recent decades. This rise can be attributed to factors such as the aging population, shifts in lifestyle behaviors, and environmental influences.
   
• For instance, as per Cancer Research UK, pancreatic cancer ranks as the tenth most frequently diagnosed cancer in the UK. Therefore, with pancreatic cancer becoming more prevalent, there is a growing need for dependable and precise diagnostic methods to identify the disease in its initial stages, when treatment interventions tend to be most impactful.
   

Japan pancreatic cancer diagnostic market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Government initiatives aimed at cancer research and awareness campaigns, along with increased funding for pancreatic cancer research, are playing a significant role in propelling the market growth in Japan.
   
• These initiatives not only raise public awareness about pancreatic cancer but also promote early detection and screening programs, leading to higher demand for diagnostic services.
   

The pancreatic cancer diagnostic market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Efforts to improve access to healthcare services, particularly in rural and underserved areas of Saudi Arabia, are making pancreatic cancer diagnostics more accessible to a larger portion of the population. This increased accessibility is driving up demand for diagnostic services, thereby propelling the market growth.
   

Pancreatic Cancer Diagnostic Market Share

The pancreatic cancer diagnostic sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.
 

Pancreatic Cancer Diagnostic Market Companies

Some of the eminent market participants operating in the pancreatic cancer diagnostic industry include

• Abbott Laboratories
• Agilent Technologies, Inc.
• ASURAGEN, INC.
• Becton, Dickinson and Company
• BioMarker Strategies
• Canon Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• GE HealthCare Technologies Inc.
• Hitachi, Ltd.
• Illumina, Inc.
• Koninklijke Philips N.V.
• Myriad Genetics, Inc.
• Prestige Biopharma Limited (PBP)
• QIAGEN N.V.
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
   

Pancreatic Cancer Diagnostic Industry News

• In May 2024, GE Healthcare has introduced Revolution RT, a novel radiation therapy computed tomography (CT) solution designed to enhance imaging accuracy and streamline simulation workflow for a more personalized oncology care experience for clinicians and patients. This product launch is expected to give GE Healthcare a competitive advantage in the field of medical imaging.
   

The pancreatic cancer diagnostic market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Consumables

Market, By Test Type

• Imaging test
  • CT scan
  • MRI
  • Ultrasound
  • PET
  • Other imaging tests
• Biopsy
• Blood test
  • Liver function tests
  • Tumor markers
  • Other blood tests
• Other test types

Market, By Cancer Type

• Exocrine
  • Adenocarcinoma
  • Squamous cell carcinoma
  • Adenosquamous carcinoma
  • Colloid carcinoma
• Endocrine

Market, By End-use

• Hospitals and clinics
• Diagnostic laboratories
• Diagnostic imaging centers
• Cancer research institutes

The above information is provided for the following regions and countries

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa